Ever wonder what The ROS1ders do to accelerate ROS1+ cancer research? Join us for a Zoom webinar titled, “Searching for a Cure: The ROS1 Cancer Model Project” on Tuesday November 9 at 2 pm Pacific Standard Time. Moderator Janet Freeman-Daily of The ROS1ders will be joined by researcher Anh Le of the University of Colorado … Continue reading The ROS1ders host “Searching for a Cure–The ROS1 Cancer Model Project” webinar November 9, 2021
Today The ROS1ders published a white paper titled, “Sustaining and Accelerating Research for ROS1 Cancer.” The document summarizes key themes and subsequent discussions from two ROS1ders Research Roundtable virtual meetings, which brought together members of The ROS1ders with leading ROS1 clinicians and researchers. The report also offers a “Call to Action” to help move ROS1 … Continue reading The ROS1ders publishes report to move ROS1+ cancer research forward
Lung Cancer Canada (LCC) is seeking ROS1 positive non-small cell lung cancer (NSCLC) patients and caregivers who have past or present treatment experience with ENTRECTINIB to share their experiences. This information will be used to provide patient/caregiver input that will help in determining accessibility of this drug for lung cancer patients in Canada. LCC and … Continue reading ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!
Dear Turning Point Therapeutics, Thank you so much for inviting me to speak to your employees about my personal ROS1 lung cancer story and the work of The ROS1ders. I truly appreciate your willingness to consider a patient perspective on ways to improve awareness of and access to biomarker testing and clinical trials for cancer patients. … Continue reading Thanks to ROS1ders’ Partner Turning Point Therapeutics
The second issue of our newsletter was released just over two weeks ago. For those who have missed it, you can grab it here : Ros1derings : August edition Contents include: A feature about Luna Okada, a 6.5 year ROS1der Some numbers about Xalkori use Fundraising updates Tips for traveling with stage 4 cancer An … Continue reading Ros1derings : August Edition
Yesterday the pan-Canadian Oncology Drug Review (pCODR) process gave a positive initial recommendation for first-line crizotinib for ROS1+ NSCLC based on clear phase 2 data & Real World Evidence. A randomized Phase 3 study was not required. This is an essential step towards getting crizotinib reimbursed for patients across Canada. This submission was led by … Continue reading pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC